Medicare will continue to increase its efforts to cut spending through aggressive review of claims and the use of new fraud and abuse regulations. Providers must be especially careful to provide correct procedure codes that define precisely what services have been provided and accurate diagnosis codes that link those procedures or tests to an appropriate diagnosis. Medicare reimbursement rules for clinical laboratory procedures are explained, including the proper use of procedure and diagnosis codes. Coding and payment for new automated test panels are discussed, as well as the economic consequences of using smaller panels. Medicare coverage requirements, including medical necessity, are described, as well as the proper use of advance beneficiary notices and the Medicare appeals process.
Medicare Payment for Clinical Laboratory Services
Medicare consists of two parts: Medicare Part A covers inpatient hospitalization costs, once the annual deductible has been met, for almost everyone age 65 and older plus the permanently disabled and those with chronic renal disease. Coverage under Part A is automatic. Payment for inpatient care in most hospitals is based on a fixed fee determined for each diagnosis (diagnosis-related groups, DRGs). 1 DRGs are not applied to physician services. Laboratory tests performed for Medicare inpatients are considered a part of the DRG payment. Medicare Part B covers physician services, outpatient clinical laboratory, and x-ray tests for eligible persons along with other medical services and supplies not covered under Part A. Part B is voluntary; however, most who are eligible sign up. There is an annual deductible and a 20% co-payment for all Part B services except outpatient clinical laboratory services.
Most clinical laboratory procedures are paid from laboratory fee schedules issued by individual Medicare carriers. Medicare carriers are contractors, usually large insurance companies, who administer Part B Medicare services in each state. There are 57 carriers, including one for each state and territory plus two in California and three in New York. All physician services, including pathology services not included in the laboratory fee schedule, are paid according to the Physician Fee Schedule. Unlike the laboratory fee schedule, under this schedule co-payments of 20% are collected from the beneficiary so that the actual payment received from Medicare for a given procedure is 80% of the Physician Fee Schedule amount.
Before Medicare pays for any test or diagnostic service, two basic criteria must be met: (a) the service must be covered by Medicare, and (b) the service must be medically necessary and indicated. Once these two criteria are met, Medicare pays for most clinical laboratory tests based on the applicable Laboratory Fee Schedule. Each carrier publishes a unique laboratory fee schedule and adjusts payment levels as determined by Congress during the annual budget process. Updates, when granted, are effective January 1st.
national fee limitations
National caps apply to most laboratory tests. These caps define the maximum amount a carrier may pay for a given test. The 1998 National Limitation amounts for any given test are based on 74% of the median amount listed on all carriers' fee schedules for a particular laboratory test. National caps were reduced from 76% to 74% effective January 1, 1998, resulting in a reduction of 2.63% for most clinical laboratory tests.
Fee schedules may be adjusted only by statutory changes approved by Congress. When the fee schedule is adjusted by a given percentage, national caps are adjusted up or down by the same amount. Medicare payment for clinical laboratory tests is always the lowest of the fee schedule, the national cap, or the actual amount billed. The changes shown in Table 1 have been made to laboratory fees since 1984, when the Laboratory Fee Schedule was established. The dollar amounts at the right-hand side of Table 1 show the effect of fee schedule changes on a test that was reimbursed at $10.00 in 1984.
Certain clinical diagnosis procedures listed in the Pathology and Laboratory sections of the Physicians' Current Procedural Terminology (CPT) (1) are not considered a part of the laboratory fee schedule. The procedures listed below are paid from the Physician Fee Schedule at 80% of the amount listed on that fee schedule. The beneficiary is responsible for the remaining 20% once the annual deductible has been met. These procedures are not subject to national limitations:
Clinical pathology consultations Bone marrow smears and biopsy Blood bank physician services Skin tests Anatomical and surgical pathology services Duodenal and gastric intubation Sputum and sweat collection Medicare tests must be billed on an assigned basis. This means that the provider must accept the Medicare reimbursement as payment in full for any covered laboratory test. Medicare patients may not be billed for any additional amounts for covered tests. (See below for policies regarding tests that are not covered by Medicare). Medicare patients may be billed for non-covered services. The mandatory assignment requirement for laboratory tests applies regardless of whether the physician is participating (accepts assignment for all Medicare services) or non-participating (does not accept assignment for all Medicare services).
Direct billing is also required for all Medicare-reimbursed laboratory tests. Tests must be billed directly to Medicare by the laboratory or physician performing the tests. If an outside laboratory performs a test on a referral from a physician, only the reference laboratory may legally bill Medicare for the procedure.
However, hospitals and reference laboratories that send specimens to other laboratories may bill Medicare for tests performed by the other laboratories if the referring laboratory meets any one of the following three exceptions:
(a) The referring laboratory is located in or is part of a rural hospital; (b) The referring laboratory is wholly owned by the reference laboratory, or the referring laboratory wholly owns the reference laboratory, or both referring laboratory and reference laboratory are wholly owned by a third entity; or (c) No more than 30% of the clinical diagnostic tests for which a laboratory receives requests annually are performed by another laboratory other than an ownership-related laboratory.
For the purpose of the 30% exception, each CPT code billed counts as one test. For example, when CPT code 80054 is billed, it is counted as one test although 12 tests are performed.
The Health Care Financing Administration Common Procedure Coding System
Health Care Financing Administration (HCFA) Common Procedure Coding System (HCPCS) codes were created as a common coding system to be used nationally for processing Medicare claims. HCPCS codes must be used when preparing claims for Medicare and Medicaid patients. The HCPCS system consists of the following three levels: Level I, which constitutes the major part of the system, is the CPT coding system. For most claims submitted, the CPT code is all that is required.
Level II, National HCPCS Codes, begin with a letter (A-V) and are followed by four numbers. Most of these codes are used for describing supplies and do not apply to laboratory and pathology procedures. These codes are the same throughout the US.
Level III, Local or Intermediary HCPCS codes, begin with W-Z or S and are followed by four digits. These codes are established by local Medicare carriers and are seldom used.
When code levels overlap, local codes have top priority, national codes second, and CPT codes lowest priority. CPT codes are revised and published annually by the American Medical Association (AMA). Of the Ͼ7000 procedures listed, ϳ950 apply to clinical laboratory tests and pathology services. The official AMA-published CPT manual together with its comprehensive cross index should always be used as the primary tool when searching for a particular procedure or test.
Many payers interpret and apply coding rules in unique and sometimes arbitrary ways. The only way to assure full reimbursement for any given procedure is to regularly review claims payments. The success of a coding strategy can be verified only by submitting claims, monitoring the payments received, and comparing the amounts actually paid to the Medicare fee schedules.
Laboratory tests are listed in the CPT by a common procedure name followed by additional information that describes the method, specimen source, or other details. The common procedure name is not repeated when used with more than one code. Care must be taken in reading individual entries to refer back to the common name that precedes the semicolon and to see if any subheadings apply more specifically to the test being coded than the principal code.
procedure code modifiers
Procedure code modifiers are two-digit codes added to the basic five-digit CPT code. Modifiers are used to describe unusual circumstances or to provide additional information regarding a test or procedure. HCFA has created the following additional modifiers which may be used in submitting Medicare claims.
-GA, waiver of liability statement on file. This modifier is used to indicate that the provider has notified a Medicare patient that the test performed may not be reimbursed by Medicare and may be billed to the patient. Situationspecific waivers of liability must be obtained by a provider and signed by the patient if the patient is to be billed for tests or other services not covered by Medicare.
-GB, distinct procedural service. This modifier is used to indicate that a procedure or service is distinct or separate from other service(s) performed on the same day. For example, performance of a follow-up test after obtaining an abnormal result from a more general clinical test. Physician laboratories may charge for specimen collection only when (a) it is accepted and prevailing practice among physicians in the locality to make a separate charge for drawing or collecting a specimen, and (b) it is the customary practice of the physician performing such a service to bill separately for specimen collection. In other words, physicians may collect the $3.00 Medicare venipuncture fee only if they also charge other payers for blood draws.
Specimen collection fees are also paid when it is medically necessary for a laboratory technician to draw a specimen from either a nursing home or homebound patient. The technician must personally draw the specimen. When a laboratory performs the specimen collection, it may receive payment both for the draw and the associated travel to obtain the specimen(s) for testing. Payment may be made to the laboratory even if the nursing facility has on-duty personnel qualified to perform the specimen collection. When the nursing home performs the specimen collection, it may receive payment only for the draw. Specimen collection performed by nursing home personnel for patients covered under Medicare Part A is paid for as part of the payment to the facility for its reasonable costs, not on the basis of the specimen collection fee.
The $3.00 Medicare specimen collection fee does not apply to non-routine venipuncture or arterial punctures. Arterial punctures for blood gas testing should be coded as CPT 36600 (arterial puncture, withdrawal of blood for diagnosis). Non-routine venipunctures, such as those common to pediatrics and those performed in atypical vein sites, should be coded using cardiovascular codes, 36400-36410 or 36420-36425. Medicare reimbursement for these procedures is paid from the Physicians' Medicare Fee Schedule rather than the Medicare Laboratory Fee Schedule.
A code for 24-h urine specimens (81050, volume measurement for timed collection, each) was added in 1993 and is used whenever a volumetric measure of urine is required to report a test result.
Travel Allowance Codes
Travel allowance codes are used to identify estimated travel costs when collecting a specimen from a nursing home or homebound patient. A separate fee is payable to cover transportation and expenses for trained personnel who travel to a nursing home or homebound patient to collect a sample. This allowance is made only when a specimen collection fee would be payable. No travel allowance is made when the technician merely performs a messenger service to pick up a specimen drawn by a physician or nursing home personnel. Furthermore, the travel allowance may not be paid to a physician unless the trip to the homebound or nursing home patient was solely for the purpose of drawing a specimen.
HCPCS codes used for travel allowances for Medicare claims are as follows:
P9603 TRAVEL ALLOWANCE-ONE WAY: in connection with medically necessary laboratory specimen collection drawn from homebound or nursing home patient, prorated as miles actually traveled (carrier allowance on per mile basis); or P9604 TRAVEL ALLOWANCE-ONE WAY: in connection with medically necessary laboratory specimen collection drawn from homebound or nursing home patient, prorated as a trip charge (carrier allowance on flat fee basis).
Drug Testing Codes
The following codes are to be used for qualitative instrumental methods: 80100 DRUG SCREEN: multiple classes, each procedure 80101 DRUG SCREEN: single class, each procedure 80102 DRUG CONFIRMATION: each procedure Quantitative assays should be coded using the appropriate method code or 83520 (immunoassay, other than antibody or infectious agent antigen, quantitative, not otherwise specified).
CPT code 80100 or 80101 is used for the initial screen, depending on whether the method detects multiple classes or a single class of drugs. Each confirmatory identification procedure is coded separately using 80102. These codes may be used in addition to the codes listed in the Therapeutic Drug Assay section of the CPT if the drug(s) determined qualitatively is subsequently quantified.
For example, an overdose of phenobarbital is suspected after obtaining a positive result for a urine screen for barbiturates. A quantitative serum assay for phenobarbital is then performed. Coding would be as follows: CPT codes for percutaneous (scratch, puncture, or prick), intracutaneous (intradermal), and patch tests include test performance, evaluation, and correlation with the patient's history, physical examination, and other observations. The number of tests should be dependent upon history, physical findings, and clinical judgment. All patients should not receive the same number or type of sensitivity tests.
Molecular Diagnostics Procedures
Molecular diagnostics procedures are coded by procedure rather than analyte using the following codes: 83890 MOLECULAR DIAGNOSTICS: molecular isolation or extraction 
Antibody Identification Codes
Antibody identification codes are organized together in the Immunology section of the CPT (codes 86602 through 86804). These procedures must be coded as precisely as possible. When multiple tests are performed to detect antibodies to a specific organism or class of immunoglobulin, each assay is to be coded separately.
For example, if antibodies to Coxsackie A and B viruses are determined using two separate assays, the following codes would be used: 
Unlisted Procedure Codes
When a specific analyte is not listed in the CPT, an unlisted procedure code may be used. However, these codes should be used only as a last resort because many payers will require additional "development" or explanation of why the test was performed. No Medicare fee schedule amounts are published for these codes.
Method Codes
When a specific test analyte can not be found in the CPT, a method code may be used to define the test performed. Such codes may be used only when a more specific code is not available.
Changes in the 1998 CPT Under the old rules, all automated multichannel tests were to be bundled into the corresponding CPT code for the total number of automated multichannel tests performed. With the demise of the automated multichannel test codes from the CPT, Medicare has adopted the following new coding rules, which no longer require bundling of these tests.
Tests on Medicare's uniform list of automated procedures may be billed using: This new policy means that it is now impossible to improperly unbundle automated multichannel because any combination of individual tests and panels that contain automated, multichannel tests are to be accepted by Medicare Carriers.
Medicare Payment Policy for Automated, Multichannel Tests
Medicare has retained the automated, multichannel fee schedule for reimbursement purposes. Last year's fees have been updated to yield the 1998 fee schedule (Table 2) Step 1: Unbundle each panel into automated and nonautomated tests; 2 Because total and direct bilirubin are coded using the same CPT code (82251), HCFA has chosen to count the CPT codes rather than the number of tests and pay this six-test panel as though it contained only five tests. The old Hepatic Function Panel (80058) included bilirubin (total or direct), which when coded separately is 82250. The new Hepatic Function Panel includes bilirubin (total and direct), which when coded separately is 82251.
Step 2: Eliminate all duplicate tests resulting from overlapping panel test compositions;
Step 3: Rebundle all remaining automated tests together and pay according to the updated automated, multichannel fee schedule (see above); and Step 4: Pay all nonautomated tests individually based on the applicable laboratory fee schedule.
Although carriers have been instructed to install edits to accomplish the proper rebundling and payment for unbundled claims, it remains to be seen how accurate their reimbursement will be. It would be wise to monitor payments and Explanation of Benefits summaries for all automated tests and panels to ensure that payments are correct. If a carrier does not reimburse correctly for the tests submitted and overpays and the provider does not refund an overpayment, Medicare at a later date may accuse the provider of making a False Claim. Likewise, if the carrier underpays, the provider needs to refile the claim to receive proper payment. Thus, it would be wise to monitor all payments and promptly refund or refile to make sure that no liability is incurred for overpayments and that no payments are less than they should be. a These payment codes are used by HCFA as an internal reference when determining payment. They are not to be used to submit claims for automated tests. Claims submitted using these codes will be denied.
Example I: electrolytes plus bun and creatinine Starting January 1, 1998, annual mammograms (annually after age 40) and screening pelvic exams (every 3 years) will be covered, as well as annual fecal occult blood tests (beginning at age 50). As of July 1, 1998, coverage begins for expanded diabetes self-management training and bone mass measurement. Coverage for prostate cancer screening using prostate-specific antigen and a digital rectal examination begins January 1, 2000.
Medicare requires a diagnosis code (ICD-9) (2) for all laboratory tests as a means of verifying medical necessity.
Carriers have been instructed to review claims for patterns of high utilization of profiles with large numbers of tests and, if documentation (i.e., patient records and chart notes) does not support Medicare coverage, to recoup payments made in the past. Such actions can also put a provider at risk of prosecution by the Medicare Office of Inspector General under the False Claims Act for submission of medically unnecessary claims.
However, HCFA has stated that for automated, multichannel tests only: "When a physician orders automated tests on a test-by-test basis, that is, not as a part of a custom panel, each of the tests is to be considered medically necessary."
When more than one automated, multichannel test is ordered individually, documentation supporting the medical necessity for every individual test is not required. In other words, a single valid medically necessary diagnosis can be used for all automated, multichannel tests ordered and performed on the same date of service so long as the tests are ordered individually by the physician. HCFA has also stated that the new automated, multichannel test panels as well as organ and disease panels are to be considered to be individual tests for medical necessity documentation purposes.
A special QP modifier is used to indicate that automated, multichannel tests were individually ordered and as such are not subject to individual documentation of medical necessity.
Example
Carbon dioxide, chloride, potassium, sodium, BUN, and creatinine are ordered on the same date of service.
If ordered as and billed as: Medical necessity is assumed and only one diagnosis code is required for all of the tests (unless local medical review policy requires specific ICD-9 codes for these tests).
If ordered as:
and billed as:
Medical necessity is also assumed, and only one diagnosis code is required for all of the tests (unless local medical review policy requires specific ICD-9 codes for these tests). Note that this panel cannot be coded as a Liver panel, 80058, because it does not include direct bilirubin.
A number of tests commonly included in chemistry profiles or general health panels do not appear on the automated multichannel chemistry list in the CPT. 
Local Medical Review Policy
Local medical review policy dictates the coverage for clinical laboratory tests in regard to medical necessity issues. The local medical review policy typically includes:
• Indications and limitations of coverage • Covered ICD-9 codes • Reasons for non-coverage • Non-covered ICD-9 codes • Documentation requirements Local medical review policy may be published for a single assay, disease, or group of tests. Most policies connect with a single CPT code, but some apply to a group of related codes. Applicable CPT codes are cited at the beginning of each policy.
Medical Necessity Enforcement and Penalties
Providers can be exposed to serious legal consequences when Medicare pays for services that are later found to be medically unnecessary. Until recently, such overpayments were treated as recovery actions by the carrier and subject only to the amount of the overpayment plus interest. However, as Congress and HCFA seek ways to reduce Medicare growth, increased attention is being paid to fines and penalties as a way to both save money and generate new revenue, which can be used to finance further investigations and increase program compliance.
During the past several years, the Justice Department and HCFA's Office of Inspector General have relied more and more on the False Claims Act to seek significant penalties and settlements in cases involving improper coding, medical necessity issues, and unbundling violations. The False Claims Act can be used to prosecute any person who knowingly presents a false or fraudulent claim for payment to the US Government. In 1986, the Act was amended to provide that "no proof of specific intent to defraud is required" and to include imposition of treble damages plus a penalty of not less than $5000 or more than $10 000 for each claim submitted.
The Health Insurance and Accountability Act of 1996 (Public Law 104-191) also includes a number of important amendments to the Civil Monetary Penalties Law regarding penalties for filing medically unnecessary claims to any federally funded health care program, including the following specific new offenses:
• Medical necessity offenses: "submission of a claim which a person knows or should know is for a medical item or service which is not medically necessary" • Upcoding offenses: "a pattern or practice of presenting a claim based on a code which the person knows or should have known will result in greater payment than appropriate"
The penalties for the above offenses include fines of $2000 to $10 000 per line item (CPT Code) and treble the amount claimed. In addition, bounties of up to 10% of fines or recovered funds can be granted to virtually anyone (patients, employees, and others) who reports allegations of fraud or abuse or sanctionable offenses.
Billing Medicare Patients for Services That May be Denied
Medicare patients may be billed for services that are clearly not covered. For example, routine physicals or screening tests such as total cholesterol or when there is no indication that the test is medically necessary. However, when a Medicare carrier is likely to deny payment because of medical necessity policy (either as stated in their written Medical Review Policy or upon examination of individual claims), the patient must be informed and consent to pay for the service before it is performed. Otherwise, the patient has no obligation to pay for the test.
An Advance Beneficiary Notice (ABN; sometimes called a patient waiver form) is used to document that the patient is aware that Medicare may not pay and has agreed to pay the provider in the event payment is denied. Each ABN must be specific to the service provided and the reason that Medicare may not pay for the service. Blanket waivers for all Medicare patients are not allowed.
The CPT code modifier, -GA (Waiver of Liability Statement on file), is used to indicate that the provider has notified the Medicare patient that the test performed may not be reimbursed by Medicare and may be billed to the patient.
An ABN (Waiver of Liability) must:
(a) be in writing; (b) be obtained prior to the beneficiary receiving the service; (c) clearly identify the particular service; (d) state that the provider believes Medicare is likely to deny payment for the service; (e) give the reason(s) that the provider believes that Medicare is likely to deny payment for the specific service; and (f) include the beneficiary's signature and date.
Routine notices to beneficiaries that do nothing more than state that Medicare denial of payment is possible, or that the provider never knows whether Medicare will pay for a service, will not be considered acceptable evidence of advance notice. Unacceptable practices include (a) giving notice for all claims or services; (b) failing to list the specific reason or rationale for likely denial; and (c) failing to state the particular service which Medicare is likely to deny.
The sample ABN shown meets the statutory requirements as outlined above.
Limiting Liability Relative to Medical Necessity Issues
The following actions should be useful in dealing with the new medical necessity rules: 
How to Appeal Medicare Denials
Medicare denials of payment based on medical necessity that are believed to be incorrect or clinically inappropriate may be appealed using the process outlined below. Statutory exclusions, i.e., services defined as non-payable under Medicare law, cannot be appealed. For example, denials based on any of the following reasons may be contested using the appeals process:
(a) the test or procedure is not medically necessary (whether or not based on carrier medical review policy); (b) inappropriate coding practice; (c) the test is not recognized as generally accepted medical practice by carrier; (d) an assay is arbitrarily defined as screening test; or (e) the test is considered a "research" procedure. 1998 Denial of payment for the following services, which are never covered by Medicare, may not be appealed:
Clinical Chemistry
(a) screening tests for asymptomatic patients; (b) routine physicals; (c) most preventive care; and (d) patient-requested tests that the physician knows, or should know, do not meet the Medicare carrier's medical necessity criteria.
The amount paid for any given procedure, as defined on the carrier fee schedule, may not be appealed because these fees are set and can be modified in most cases only by Congress.
STEP 1: Within 6 months of receiving an Explanation of Benefits form, laboratories have the right to request a review by an employee not involved in the original determination. This step requires requesting a review of attached denial(s) and the reason the claim(s) should be paid; this can be done with HCFA form 1964. The carrier must acknowledge the request within 45 days, and the response must come from someone not involved in the original payment determination.
STEP 2: If the result of the carrier review is still unsatisfactory, and the amount in question is at least $100, laboratories may request a fair hearing within 6 months of an adverse review determination.
A detailed letter or HCFA form 1965 should be used. The hearing may be in person or via phone, or can rely only on submitted documents. The carrier must acknowledge the request within 45 days and arrange for the date and time of the hearing. This step provides the opportunity to present the case in person, usually to the Medical Review office and his/her staff. STEP 3: If the matter is not resolved by the Fair Hearing, and the amount in question is at least $500, one may request a hearing by an administrative law judge within 60 days of an adverse fair hearing determination. The administrative law judge is bound only by Medicare law and regulations, not HCFA's administrative directives to carriers or any individual carrier's interpretation of HCFA policy. The hearing may be in person or via phone. Unsatisfactory determinations by an administrative law judge can be appealed to US District Court for amounts over $1000.
Medicare will only pay for services that it determines to be reasonable and necessary under Section 1862(a) (1) of the Medicare law. If Medicare determines that a particular service, although it would otherwise be covered, is not reasonable and necessary under Medicare program standards, Medicare will deny payment for that service. 
